ObsEva Files Year End 2022 Financial Statements
31 mars 2023 16h01 HE
|
ObsEva SA
ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market:...
ProPhase Labs to Host 2022 Year End Financial Results Conference Call on Tuesday, March 28, 2023 at 11:00 a.m. Eastern Time
21 mars 2023 08h00 HE
|
ProPhase Labs, Inc.
GARDEN CITY, NY, March 21, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, will hold a conference call on...
ObsEva Announces Year End 2020 Financial Results and Business Update
05 mars 2021 01h00 HE
|
ObsEva SA
-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3...
ObsEva SA Link to Annual Report 2019
05 mars 2020 04h43 HE
|
ObsEva SA
Geneva, Switzerland and Boston, MA – March 5, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva Announces Year End 2019 Financial Results and Business Update
05 mars 2020 01h00 HE
|
ObsEva SA
Primary endpoint achieved in 94% of women in linzagolix Phase 3 PRIMROSE 2 trial in uterine fibroids Linzagolix Phase 3 PRIMROSE 1 six-month primary endpoint results and PRIMROSE 2 twelve-month...
VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results
25 févr. 2019 08h00 HE
|
VBI Vaccines, Inc.
Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and...